Primary Adrenal Insufficiency: Diagnosis and Management (According to the 17th European Congress of Endocrinology, Dublin, Ireland 16–20 May, 2015)

Main Article Content

Yu.I Komisarenko
I.V. Sydorov
M.I. Bobryk
V.M. Reznichenko


Primary adrenal insufficiency (PAI, Addison’s disease) — treatable disease, remains potentially lethal. PAI is often detected in the state of adrenal crisis, and timely emergency treatment can prevent the death. To minimize the risk of both adrenal crises and side effects of substitution therapy for this disease, there are extremely important individualization of treatment regimens (optimal drugs are hydrocortisone preparations combined with fludrocortisone), detection of associated autoimmune diseases, patient’s training of both to adjust the daily therapy and to do self-injections of glucocorticoids in moderately severe comorbidities. Life expectancy of patients with adequate therapy and regular monitoring does not differ from the average one.

Article Details

How to Cite
Komisarenko, Y., I. Sydorov, M. Bobryk, and V. Reznichenko. “Primary Adrenal Insufficiency: Diagnosis and Management (According to the 17th European Congress of Endocrinology, Dublin, Ireland 16–20 May, 2015)”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), no. 7.71, Dec. 2015, pp. 51-58, doi:10.22141/2224-0721.7.71.2015.72596.
Proceedings of the Conference


Erichsen M.M., Lovas K., Skinningsrud B. et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry // J. Clin. Endocrinol. Metab. 2009; 94: 4882-90.

Soderbergh A., Winqvist O., Norheim I. et al. Adrenal autoantibodies and organ-specific autoimmunity in patients with Addison’s disease // Clin. Endocrinol. 1996; 45: 453-60.

Betterle C., Dal Pra C., Mantero F., Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction // Endocr. Rev. 2002; 23: 327-64.

Fichna M., Fichna P., Gryczynska M., Walkowiak J., Zurawek M., Sowinski J. Screening for associated autoimmune disorders in Polish patients with Addison’s disease // Endocrine 2010; 37: 349-60.

Reato G., Morlin L., Chen S. et al. Premature ovarian failure in patients with autoimmune Addison’s disease: clinical, genetic, and immunological evaluation // J. Clin. Endocrinol. Metab. 2011; 96: E1255-61.

Soderbergh A., Myhre A.G., Ekwall O. et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I // J. Clin. Endocrinol. Metab. 2004; 89: 557-62.

Myhre A.G., Aarsetoy H., Undlien D.E., Hovdenak N., Aksnes L., Husebye E.S. High frequency of coeliac disease among patients with autoimmune adrenocortical failure // Scand. J. Gastroenterol. 2003; 38: 511-5.

Ghaderi M., Gambelunghe G., Tortoioli C. et al. MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency // J. Clin. Endocrinol. Metab. 2006; 91: 4107-11.

Elfstrom P., Montgomery S.M., Kampe O., Ekbom A., Ludvigsson J.F. Risk of primary adrenal insufficiency in patients with celiac disease // J. Clin. Endocrinol. Metab. 2007; 92: 3595-8.

Neufeld M., Maclaren N., Blizzard R. Autoimmune polyglandular syndromes // Pediatr. Ann. 1980; 9: 154-62.

Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy // J. Clin. Endocrinol. Metab. 2006; 91: 2843-50.

Husebye E.S., Perheentupa J., Rautemaa R., Kampe O. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I // J. Intern. Med. 2009; 265: 514-29.

Eisenbarth G.S., Gottlieb P.A. Autoimmune polyendocrine syndromes // N. Engl. J. Med. 2004; 350: 2068-79.

Bjornsdottir S., Sundstrom A., Ludvigsson J.F., Blomqvist P., Kampe O., Bensing S. Drug prescription patterns in patients with Addison’s disease: a Swedish population-based cohort study // J. Clin. Endocrinol. Metab. 2013; 98: 2009-18.

Bjornsdottir S., Saaf M., Bensing S., Kampe O., Michaelsson K., Ludvigsson J.F. Risk of hip fracture in Addison’s disease: a population-based cohort study // J. Intern. Med. 2011; 270: 187-95.

Arlt W., Callies F., van Vlijmen J.C. et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency // N. Engl. J. Med. 1999; 341: 1013-20.

Ahonen P., Myllarniemi S., Sipila I., Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients // N. Engl. J. Med. 1990; 322: 1829-36.

Cooper M.S., Stewart P.M. Corticosteroid insufficiency in acutely ill patients // N. Engl. J. Med. 2003; 348: 727-34.

Hangaard J., Andersen M., Grodum E., Koldkjaer O., Hagen C. Pulsatile thyrotropin secretion in patients with Addison’s di­sease during variable glucocorticoid therapy // J. Clin. Endocrinol. Metab. 1996; 81: 2502-7.

Winqvist O., Karlsson F.A., Kampe O. 21-Hydroxylase, a major autoantigen in idiopathic Addison’s disease // Lancet 1992; 339: 1559-62.

Meager A., Visvalingam K., Peterson P. et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1 // PLoS Med. 2006; 3: e289.

Oftedal B.E., Wolff A.S., Bratland E. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I // Clin. Immunol. 2008; 129: 163-9.

Ahlgren K.M., Moretti S., Lundgren B.A. et al. Increased IL-17A secretion in response to Candida albicans in autoimmune polyendocrine syndrome type 1 and its animal model // Eur. J. Immunol. 2011; 41: 235-45.

Sanaker P.S., Husebye E.S., Fondenes O., Bindoff L.A. Clinical evolution of Kearns-Sayre syndrome with polyendocrinopathy and respiratory failure // Acta Neurol. Scand. Suppl. 2007; 187: 64-7.

Falorni A., Laureti S., De Bellis A. et al. Italian addison network study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency // J. Clin. Endocrinol. Metab. 2004; 89: 1598-604.

Mitchell A.L., Pearce S.H. Autoimmune Addison disease: pathophysiology and genetic complexity // Nat. Rev. Endocrinol. 2012; 8: 306-16.

Skinningsrud B., Husebye E.S., Gilfillan G.D et al.

X-linked congenital adrenal hypoplasia with hypogonadotropic hypogonadism caused by an inversion disrupting a conserved noncoding element upstream of the NR0B1 (DAX1) gene // J. Clin. Endocrinol. Metab. 2009; 94: 4086-93.

Esteban N.V., Loughlin T., Yergey A.L. et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry // J. Clin. Endocrinol. Metab. 1991; 72: 39-45.

Barbetta L., Dall’Asta C., Re T., Libe R., Costa E., Ambrosi B. Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism // J. Endocrinol. Invest. 2005; 28: 632-7.

Ekman B., Bachrach-Lindstrom M., Lindstrom T., Wahlberg J., Blomgren J., Arnqvist H.J. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency // Clin. Endocrinol. 2012; 77: 18-25.

Lebbe M., Arlt W. What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy? // Clin. Endocrinol. 2013; 78: 497-502.

Methlie P., Husebye E.E., Hustad S., Lien E.A., Lovas K. Grapefruit juice and licorice increase cortisol availability in patients with Addison’s disease // Eur. J. Endocrinol. 2011; 165: 761-9.

Gurnell E.M., Hunt P.J., Curran S.E. et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial // J. Clin. Endocrinol. Metab. 2008; 93: 400-9.

Winqvist O., Gustafsson J., Rorsman F., Karlsson F.A., Kampe O. Two different cytochrome P450 enzymes are the adrenal antigens in autoimmune polyendocrine syndrome type I and Addison’s disease // J. Clin. Invest. 1993; 92: 2377-85.

Most read articles by the same author(s)